US 9212364
Compositions and methods for inhibiting expression of mutant EGFR gene
granted A61KA61K31/713A61P
Quick answer
US patent 9212364 (Compositions and methods for inhibiting expression of mutant EGFR gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/713, A61P, A61P35/00